Thomas M. Sobol
Bringing the suit closer to resolution, Judge William Young issued a preliminary approval of a proposed settlement between GlaxoSmithKline and the class. Under the terms of the settlement, the defendants will pay damages of $75 million to those included in the class. Of the total settlement amount, $25 million will be allocated to consumers and $50 million will be used to pay the claims of insurers and other third-party payors.
In February of 2002, lawyers at Hagens Berman filed a class-action lawsuit against GlaxoSmithKline PLC (NYSE: GSK), SmithKline Beecham Corporation (NYSE: SBH), Beecham Group PLC, and SmithKline Beecham PLC, on behalf of consumers and third-party payors who purchased the drug Relafen or its generic alternatives.
The suit alleged that the companies who manufacture and sell Relafen unlawfully obtained a patent which allowed them to enforce a monopoly over Relafen and prevented competition by generic prescription drugs, causing consumers to pay inflated prices for the drug. The suit seeks monetary restitution for class members.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.